|
1. |
Spectral Analysis of Heart Rate Variability as a Quantitative Measure of Parasympatholytic Effect-Integrated Pharmacokinetics and Pharmacodynamics of Three Anticholinergic Drugs |
|
Therapeutic Drug Monitoring,
Volume 21,
Issue 2,
1999,
Page 141-151
Harry Scheinin,
Antti Helminen,
Sakke Huhtala,
Paula Grönroos,
Job Bosch,
Tom Kuusela,
Jussi Kanto,
Timo Kaila,
Preview
|
|
摘要:
The time course and concentration-effect relationship of parasympatholytic effects of three anticholinergic drugs were investigated using spectral analysis of heart rate (HR) variability. Single intravenous (IV) doses of atropine (10 µg/kg), glycopyrrolate (5 µg/kg), scopolamine (5 µg/kg), and placebo were given to eight healthy volunteers in a double-blind, randomized cross-over study. Electrocardiogram (ECG) was recorded at baseline and 2.5, 5, 10, 20, and 30 minutes, and 1, 1.5, 2, 3, 4, 5, and 6 hours after drug administration, while the subjects breathed at a fixed 0.25 Hz frequency. The powers of two frequency bands (low frequency [LF] = 0.07-0.15 Hz and high frequency [HF] = 0.15-0.40 Hz) were calculated using stationary time series of R-R intervals (RRI) free from ectopic beats. To perform pharmacokinetic-pharmacodynamic (PK-PD) modeling, venous plasma drug concentrations were measured. Atropine and glycopyrrolate, and, to a lesser extent, scopolamine induced decreases in HF power and increases in LF/HF ratio of HR variability, indicating parasympatholytic activity and corresponding changes in sympathovagal balance. Maximal average decreases in HF power were 99%, 94%, and 82%, respectively, but in two scopolamine subjects, a parasympathomimetic effect was dominant. Interindividual variability was least for the Hayano index of HF power (√ (RRI HF-power)/RRI*100), and profound and consistent decreases were seen after atropine and glycopyrrolate. Pharmacokinetics were best fitted to a two-compartment open model, and effect compartment link modeling using the Hayano index was performed with the atropine and glycopyrrolate data. The best description of the PK-PD relationship for both drugs was achieved using the sigmoidal Emaxmodel. Mean (±SD) EC50, sigmoidicity factor (γ), and equilibration rate constant (keO) estimates were 1.35 (±0.27) ng/mL, 6.07 (±1.98) and 11.0 (±5.28) 1/h for atropine and 1.35 (±0.49) ng/mL, 4.34 (±1.55) and 2.26 (±0.81) 1/h for glycopyrrolate. Spectral analysis of HR variability appears to be a powerful tool in monitoring parasympatholytic drug activity. A sigmoidal Emaxmodel with an extremely steep concentration-response relationship was revealed for atropine and glycopyrrolate. The effects of scopolamine were more incongruous.
ISSN:0163-4356
出版商:OVID
年代:1999
数据来源: OVID
|
2. |
Dihydropyrimidine Dehydrogenase Activity in a Korean Population |
|
Therapeutic Drug Monitoring,
Volume 21,
Issue 2,
1999,
Page 152-154
Dong-Ryul Sohn,
Moo Cho,
Pa-Jong Chung,
Preview
|
|
摘要:
Dihydropyrimidine dehydrogenase (DPD) is the major metabolic enzyme in the catabolism of 5-fluorouracil, and the activity in normal tissues shows a wide variation among individuals. Recent studies demonstrate the relevance of DPD in the pharmacokinetics, toxicity, and antitumor efficacy of 5-fluorouracil. We investigated the DPD activity in peripheral blood mononuclear cell form 114 healthy subjects in Korea. The DPD activities in healthy volunteers were shown to follow a unimodal distribution. The mean of the activity was 0.28 ± 0.16 nmol/min/mg protein. A wide (13-fold) intersubject variability was observed (range, 0.06-0.80 nmol/min/mg protein), and, on average, DPD activity in women (0.26 ± 0.14) was 13% lower than in men (0.30 ± 0.16). These findings indicate that the activity of DPD in this study was higher than in reports of research with French and white American populations.
ISSN:0163-4356
出版商:OVID
年代:1999
数据来源: OVID
|
3. |
Plasma Total Phenytoin: A Possibly Misleading Test in Developing Countries |
|
Therapeutic Drug Monitoring,
Volume 21,
Issue 2,
1999,
Page 155-160
Carolyn Fedler,
Michael Stewart,
Preview
|
|
摘要:
The use of phenytoin has increased among the rural black population in South Africa, many of whom have albumin concentrations below the accepted reference range of 35-50 g/L, related to a combination of malnutrition and late-presenting renal and hepatic disease. Because albumin concentration has a major effect on the proportion of free phenytoin in the extracellular fluid, we instituted a study of the extent of hypoalbuminemia and of the difference between "total" phenytoin (measured by immunoassay), and "corrected" phenytoin (calculated using the Sheiner-Tozer equation, which is based on a mean albumin of 40 g/L). The differences were significant (higher than 20%) in 37% of patients and led us to propose that in populations in which there is a high proportion of patients who are hypoalbuminemic, it is corrected rather than total phenytoin that should be the value reported.
ISSN:0163-4356
出版商:OVID
年代:1999
数据来源: OVID
|
4. |
Tobramycin Pharmacokinetics in Patients with Cystic Fibrosis Preceding and Following Lung Transplantation |
|
Therapeutic Drug Monitoring,
Volume 21,
Issue 2,
1999,
Page 161-165
Robert Dupuis,
Edward Sredzienski,
Preview
|
|
摘要:
The pharmacokinetics of tobramycin in patients with cystic fibrosis before and after lung transplantation were evaluated. Twenty-nine lung transplant recipients with cystic fibrosis who received at least one course of tobramycin pre- and posttransplantation were included in this study. Pharmacokinetic parameters (clearance, volume of distribution, elimination rate and half-life) were calculated using a one-compartment Bayesian method. Comparisons were made both between and within pre- and posttransplant periods for patients receiving multiple courses. Significant differences were noted. Clearance was decreased 40%, volume of distribution increased 20%, elimination rate increased 52%, and half-life increased 141%, respectively, posttransplant as compared to pretransplant. There were no differences within each time period between each tobramycin course. The results indicate that tobramycin pharmacokinetics are significantly altered in patients with cystic fibrosis after lung transplantation. Patients with cystic fibrosis require early and close monitoring of tobramycin after lung transplantation.
ISSN:0163-4356
出版商:OVID
年代:1999
数据来源: OVID
|
5. |
Effects of Carbamazepine Coadministration on Plasma Concentrations of the Enantiomers of Mianserin and of its Metabolites |
|
Therapeutic Drug Monitoring,
Volume 21,
Issue 2,
1999,
Page 166-170
Chin Eap,
Norio Yasui,
Sunao Kaneko,
Pierre Baumann,
Kerry Powell,
Koichi Otani,
Preview
|
|
摘要:
Concentrations of the enantiomers of unconjugated and of total (unconjugated plus conjugated) mianserin, desmethylmianserin and 8-hydroxymianserin were measured in 12 patients before and after the introduction of carbamazepine. The dose of mianserin was 60 mg/d, carbamazepine was coadministered at 400 mg/d for 4 weeks, and blood samples were taken at weekly intervals after the introduction of carbamazepine. Each week, carbamazepine significantly decreased plasma concentrations of unconjugated and total (S)-mianserin (the more potent enantiomer) and of unconjugated and total (R)-mianserin. On average, plasma concentrations of unconjugated and total (S)-mianserin and of unconjugated and total (R)-mianserin were 55%, 56%, 66%, and 55%, respectively, of the corresponding values before introduction of carbamazepine. These results strongly suggest the involvement of CYP3A4, the major CYP enzyme induced by carbamazepine, in the metabolism of both enantiomers of mianserin. A strong decrease in the concentrations of (S)-8-hydroxymianserin was also measured (on average, the concentrations were 69% of the corresponding values before carbamazepine introduction). Conversely, plasma concentrations of unconjugated and of total (S)-desmethylmianserin, (R)-desmethylmianserin, and (R)-8-hydroxymianserin were only slightly modified by carbamazepine. From a clinical point of view, as a therapeutic window for (S)-mianserin has been recently suggested, the dose of racemic mianserin for a patient whose (S)-mianserin concentrations have been stabilized within this therapeutic window would need to be approximately doubled if carbamazepine, at 400 mg/d, is introduced as a comedication.
ISSN:0163-4356
出版商:OVID
年代:1999
数据来源: OVID
|
6. |
Lamotrigine Drug Interactions in a TDM Material |
|
Therapeutic Drug Monitoring,
Volume 21,
Issue 2,
1999,
Page 171-174
Ylva Böttiger,
Jan-Olov Svensson,
Lars Ståhle,
Preview
|
|
摘要:
Using therapeutic drug monitoring (TDM) data from our laboratory, we have studied the concentration/dose relationship for lamotrigine and the influence of drug interactions in clinical practice. One hundred forty-nine lamotrigine samples from 104 adult patients were included in the study. The samples were collected as steady-state trough values, 9-16 hours after dose intake. Concomitant drug treatment was specified on the analysis request form. Lamotrigine serum concentrations were determined by high-performance liquid chromatography (HPLC). In 20 patients in monotherapy, the concentration/dose (C/D) ratio was 65 (range: 50-84) nmol/L/mg (mean and 95% confidence interval, antilog from lognormal distribution). In 37 patients with concomitant carbamazepine treatment, the C/D ratio was less than half that of the patients in monotherapy; 31 (21-46) nmol/L/mg, and in 14 patients with phenytoin, it was even lower; 17 (13-23) nmol/L/mg. Valproic acid significantly increased the C/D to 251 (200-320) nmol/L/mg in 13 patients. Triple therapy with valproic acid and either carbamazepine or phenytoin (23 patients) yielded a C/D slightly above that of monotherapy, whereas a few patients on phenobarbital had a C/D slightly below that of monotherapy. The within-group C/D variation was comparatively small. The C/D ratio in a mixed lamotrigine TDM material shows a widespread intra- and interindividual variation, which can largely be explained by pharmacokinetic interactions with concomitantly used antiepileptic drugs. These results support the use of TDM in lamotrigine therapy.
ISSN:0163-4356
出版商:OVID
年代:1999
数据来源: OVID
|
7. |
Influence of Oxcarbazepine and Methsuximide on Lamotrigine Concentrations in Epileptic Patients With and Without Valproic Acid Comedication: Results of a Retrospective Study |
|
Therapeutic Drug Monitoring,
Volume 21,
Issue 2,
1999,
Page 175-181
Theodor May,
Bernhard Rambeck,
Uwe Jürgens,
Preview
|
|
摘要:
The aim of this retrospective study was to investigate the influence of oxcarbazepine (OCBZ) and methsuximide (MSM) on lamotrigine (LTG) serum concentrations. The effect of OCBZ compared to carbamazepine (CBZ) and the effect of MSM on LTG serum concentrations were examined in patients with and without valproic acid (VPA) comedication. Altogether, 376 samples from 222 patients were analyzed in routine drug monitoring. Two or more serum samples from the same patient were considered only if the comedication had been changed. For statistical evaluation, regression analytical methods and an analysis of variance were performed. For the analysis of variance, the LTG serum concentration in relation to LTG dose/body weight-level-to-dose ratio (LDR), in (µg/mL)(mg/kg)-was calculated and compared for different drug combinations. The nonlinear regression analysis including the LTG dose per body weight, age, gender, and the different kinds of comedication revealed that these variables have a significant influence on LTG serum concentration (r2= 0.724). The relationship between LTG dose/body weight and serum concentration deviates only slightly from linearity, the LTG concentration was about 18% lower in women than in men, and age had a significant influence. The data indicate that children have significantly lower LTG concentrations than adults on a comparable LTG dose per body weight and that children may be more prone to enzyme induction by comedicated drugs. Methsuximide has a strong inducing effect on the LTG metabolism and decreases the LTG concentrations markedly (about 70% compared to LTG monotherapy). Carbamazepine also reduces the LTG concentrations considerably (by 54%). The inducing effect of OCBZ (29%) was less pronounced but also significant. The inducing effect of MSM, CBZ, and OCBZ was also seen in combination with VPA: VPA alone increases the LTG concentration approximately 211%, whereas in addition to MSM (8%), CBZ (21%), or OCBZ (111%), the increase of LTG was significantly smaller. The analysis of variance confirmed the results of the regression analysis. The effect of MSM on the LTG concentration should be considered if MSM is added or withdrawn in patients treated with LTG. Oxcarbazepine had a less pronounced inducing effect on LTG metabolism compared to CBZ. If CBZ is replaced by OCBZ as comedication, an increase in LTG serum concentrations should be expected.
ISSN:0163-4356
出版商:OVID
年代:1999
数据来源: OVID
|
8. |
Lamotrigine Serum Concentration-to-Dose Ratio: Influence of Age and Concomitant Antiepileptic Drugs and Dosage Implications |
|
Therapeutic Drug Monitoring,
Volume 21,
Issue 2,
1999,
Page 182-190
Juan Armijo,
Jesús Bravo,
Antonio Cuadrado,
José Herranz,
Preview
|
|
摘要:
Using bivariate and multivariate methods, we retrospectively analyzed the influence of patient age and the use of concomitant antiepileptic drugs (AEDs) on the lamotrigine (LTG) concentration-to-dose (C/D) ratio in samples from 164 patients (68 children, 96 adults) with epilepsy receiving LTG alone (n = 28) or in combination with various antiepileptic drugs (n = 136). The LTG C/D ratio increased with age in children receiving LTG alone (r= 0.60,p< 0.01), but decreased with age in adults receiving LTG and inducers (r= -0.42,p< 0.001). In patients receiving LTG and inducers, the ratio was statistically lower in those younger than 9 years of age (0.23 ± 0.08) and older than 30 years of age (0.32 ± 0.15) than it was in those between 9 and 30 years of age (0.44 ± 0.15). The mean LTG C/D ratio was 0.37 ± 0.15 in patients receiving LTG and inducers (n = 92), 0.84 ± 0.41 in patients receiving LTG alone (n = 28), 1.09 ± 0.44 in those receiving LTG with VPA plus inducers (n = 17), and 3.41 ± 1.18 in those receiving LTG and VPA (n = 27). Differences in the LTG C/D ratio between treatment groups were similar in children and in adults. We reached the following conclusions: The LTG C/D ratio increased with age in children but may decrease with age in adults receiving concomitant enzyme-inducing AEDs; the LTG C/D ratio was 10 times lower in patients receiving LTG and inducers than in those receiving LTG and VPA (in both children and adults), and this difference was higher than the four-fold difference described for LTG half-life and the two-fold differences currently used in LTG dosage.
ISSN:0163-4356
出版商:OVID
年代:1999
数据来源: OVID
|
9. |
Stereoselective Disposition of the Antiarrhythmic Agent Mexiletine During the Concomitant Administration of Caffeine |
|
Therapeutic Drug Monitoring,
Volume 21,
Issue 2,
1999,
Page 191-199
Line Labbé,
Zohreh Abolfathi,
N. Robitaille,
François St-Maurice,
Marcel Gilbert,
Jacques Turgeon,
Preview
|
|
摘要:
Caffeine consumption is extensive in industrialized countries and its role in drug-drug interactions is often overlooked. CYP1A2, the major cytochrome P450 isoform involved in the metabolism of caffeine, has also been implicated in the formation of N-hydroxymexiletine, the major metabolite of mexiletine. Therefore, the objective of this study was to assess the effects of a clinically relevant dosage of caffeine on the stereoselective disposition of mexiletine. Fourteen healthy volunteers-10 extensive metabolizers (EMs) and 4 poor metabolizers (PMs) of CYP2D6-received a single 200 mg oral dose of racemic mexiletine hydrochloride on two occasions (1 week apart): once by itself and once during administration of caffeine (100 mg four times daily). Serial blood and urine samples were collected and pharmacokinetic parameters were estimated. Although the total clearance of mexiletine was not significantly altered by the coadministration of caffeine in EMs and PMs, a stereoselective decrease (16% in EMs and 14% in PMs) in the urinary recovery of N-hydroxymexiletine from the R-(-)-enantiomer was observed. Also, the partial metabolic clearance of R-(-)-mexiletine to N-hydroxymexiletine glucuronide was reduced from 126 ± 48 mL/min to 106 ± 32 mL/min and 152.6 (73.4-196.2) mL/min to 109 (77-127) mL/min by the coadministration of caffeine in EMs and PMs, respectively. Consequently, the R/S ratio for urinary recovery and the partial metabolic clearance of mexiletine to N-hydroxymexiletine were 28% lower during the coadministration of caffeine. In conclusion, data obtained in this study indicate that coadministration of caffeine does not lead to clinically significant changes in mexiletine plasma concentrations. However, results obtained suggest that CYP1A2 is involved in the formation of N-hydroxymexiletine.
ISSN:0163-4356
出版商:OVID
年代:1999
数据来源: OVID
|
10. |
Fluconazole Bioequivalence Study: Quantification by Tandem Mass Spectrometry |
|
Therapeutic Drug Monitoring,
Volume 21,
Issue 2,
1999,
Page 200-207
Leonardo Moraes,
Federico Lerner,
Maria E. A. Moraes,
Manuel Moraes,
Gaetano Corso,
Gilberto De Nucci,
Preview
|
|
摘要:
To develop a new method for quantifying fluoconazole in human plasma and to compare the bioavailability of two fluconazole capsule formulations, an open, randomized, two-period crossover study with a one-week washout interval was conducted in 24 healthy volunteers. Plasma samples were obtained up to 168 hours after drug administration and the serum fluoconazole concentrations were analyzed using electrospray tandem mass spectrometry coupled to liquid chromatography using multiple reaction monitoring mode. The pharmacokinetic parameters obtained for fluconazole after the administration of each formulation included the Area under the curve (AUC)(0-168h), AUC(0-∞), Cmax, Cmax/AUC(0-168h), Tmax, elimination rate constant (Ke), and half-life (T1/2). Within- and between-run imprecision was less than 2.3% and 8.2%, respectively. Inaccuracy within and between runs was -1.5% and -9.7%, respectively. The pharmacokinetic parameters for bioequivalence showed a normal distribution, and the variance of AUC(0-168h), AUC(0-∞), and Cmax were homoscedastic. The geometric mean for the Fluconal/Zoltec (Fluconal; Libbs Farmacêutica Ltda, São Paulo, Brazil; Zoltec; Laboratórios Pfizer Ltda., São Paulo, Brazil) individual percent ratio was 94.9% for AUC(0-168h), 94.7% for AUC(0-∞), 80.1% for Cmax, 102.6% for Ke, 97.5% for T1/2, and 0.93 for Tmax (arithmetic mean of individual differences). We have developed a method in which liquid chromatography is coupled with electrospray tandem mass spectrometry to improve the pharmacokinetic analysis of fluconazole. Because the 90% CI AUC is within the interval proposed for the Food and Drug Administration, we concluded that Fluconal is bioequivalent to Zoltec in terms of absorption. The CV was 27.5% for the Cmax parameter, indicating that fluconazole's absorption rate is highly variable. The European Union Regulatory Agency accepts an interval of 70-143%, and because the 90% CI for Cmax is within the interval proposed for the European Union agency, we conclude that Fluconal is bioequivalent to Zoltec for the rate of absorption.
ISSN:0163-4356
出版商:OVID
年代:1999
数据来源: OVID
|
|